Evidence map›Paper›PMID 35844683›Full record

ArticleEJHaem2021

RUNX inhibitor suppresses graft-versus-host disease through targeting

Hirohito Kubota, Tatsuya Masuda, Mina Noura, Kana Furuichi, Hidemasa Matsuo, Masahiro Hirata, Tatsuki R Kataoka, Hidefumi Hiramatsu, Takahiro Yasumi, Tatsutoshi Nakahata and 5 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJHaem, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Hirohito KubotaDepartment of Pediatrics Graduate School of Medicine Kyoto University Sakyo-ku Kyoto Japan.ORCID https://orcid.org/0000-0002-7578-006X
Tatsuya MasudaDepartment of Human Health Sciences Graduate School of Medicine Kyoto, University, Sakyo-ku Kyoto Japan.
Mina NouraDepartment of Human Health Sciences Graduate School of Medicine Kyoto, University, Sakyo-ku Kyoto Japan.
Kana FuruichiDepartment of Human Health Sciences Graduate School of Medicine Kyoto, University, Sakyo-ku Kyoto Japan.
Hidemasa MatsuoDepartment of Human Health Sciences Graduate School of Medicine Kyoto, University, Sakyo-ku Kyoto Japan.
Masahiro HirataDepartment of Diagnostic Pathology Kyoto University Hospital Sakyo-ku Kyoto Japan.
Tatsuki R KataokaDepartment of Diagnostic Pathology Kyoto University Hospital Sakyo-ku Kyoto Japan.
Hidefumi HiramatsuDepartment of Pediatrics Graduate School of Medicine Kyoto University Sakyo-ku Kyoto Japan.
Takahiro YasumiDepartment of Pediatrics Graduate School of Medicine Kyoto University Sakyo-ku Kyoto Japan.ORCID https://orcid.org/0000-0003-3257-5071
Tatsutoshi NakahataDrug Discovery Technology Development Office Center for iPS cell research and application (CiRA) Kyoto University Sakyo-ku Kyoto Japan.
Yoichi ImaiDepartment of Hematology/Oncology IMSUT Hospital The Institute of Medical Science The University of Tokyo Tokyo Japan.
Junko TakitaDepartment of Pediatrics Graduate School of Medicine Kyoto University Sakyo-ku Kyoto Japan.
Souichi AdachiDepartment of Human Health Sciences Graduate School of Medicine Kyoto, University, Sakyo-ku Kyoto Japan.
Hiroshi SugiyamaDepartment of Chemistry Graduate School of Science Kyoto University Sakyo-ku Kyoto Japan.
Yasuhiko KamikuboDepartment of Human Health Sciences Graduate School of Medicine Kyoto, University, Sakyo-ku Kyoto Japan.ORCID https://orcid.org/0000-0003-2761-8508
Kyoto University · JPKyoto University Hospital · JPTokyo Medical University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with refractory graft-versus-host disease (GVHD) have a dismal prognosis. Therefore, novel therapeutic targets are still needed to be identified. Runt-related transcriptional factor (RUNX) family transcription factors are essential transcription factors that mediate the essential roles in effector T cells. However, whether RUNX targeting can suppress, and GVHD is yet unknown. Here, we showed that RUNX family members have a redundant role in directly transactivating

Indexed as

graft‐versus‐host diseaseNFATC2polyamideRUNX

Identifiers

PMID35844683
PMCPMC9175814
OpenAlexW3164571330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.